CJC-1295 With DAC

Overview

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic research peptide that acts as a growth hormone-releasing hormone (GHRH) analog. The addition of DAC extends its half-life, allowing for prolonged and stable growth hormone release in laboratory studies. It is widely researched for its potential to support elevated and sustained growth hormone levels in test models such as laboratory rodents.

Benefits

Preclinical studies have shown that CJC-1295 with DAC can increase growth hormone secretion and elevate IGF-1 levels for an extended duration in test subjects. The DAC modification allows for less frequent administration while maintaining consistent growth hormone stimulation, making it valuable for long-term research on tissue repair, muscle development, and recovery.
Source: Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006. Link

Possible Side Effects

In research environments, test subjects given CJC-1295 with DAC may experience mild side effects such as injection site irritation, water retention, tingling or numbness, or slight changes in glucose markers. These effects vary depending on dosage, duration, and the species used in studies.
Source: Teichman SL, et al., JCEM, 2006. Link

Dosage & Administration

CJC-1295 with DAC is administered via subcutaneous injection according to controlled research protocols. Typical dosing for laboratory studies ranges from 1 mg to 2 mg per injection, with administration generally once or twice per week due to its extended half-life. Frequency and dosage depend on study design and species used.
For laboratory research use only. Not for human consumption.

Summary

CJC-1295 with DAC is a long-acting growth hormone-releasing hormone analog designed exclusively for research exploring sustained growth hormone elevation, IGF-1 support, and muscle tissue development in preclinical models. Studies show it can prolong growth hormone release with mild side effects such as injection site redness or water retention observed in test subjects. CJC-1295 DAC is typically administered via subcutaneous injection weekly or bi-weekly, with dosage tailored to the research goals and species.
Strictly for research purposes only. Not for human use.